News
SynOx Therapeutics has completed subject enrolment in its multi-centre Phase III TANGENT trial of emactuzumab for TGCT.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback